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ABSTRACT: Noncanonical amino acids form a highly diverse
pool of building blocks that can render unique physicochemical
properties to peptides and proteins. Here, four methionine
analogues with unsaturated and varying side chain lengths were
successfully incorporated at four different positions in nisin in
Lactococcus lactis through force feeding. This approach allows for
residue-specific incorporation of methionine analogues into nisin
to expand their structural diversity and alter their activity profiles. Moreover, the insertion of methionine analogues with
biorthogonal chemical reactivity, e.g., azidohomoalanine and homopropargylglycine, provides the opportunity for chemical coupling
to functional moieties and fluorescent probes as well as for intermolecular coupling of nisin variants. All resulting nisin conjugates
retained antimicrobial activity, which substantiates the potential of this method as a tool to further study its localization and mode of
action.
KEYWORDS: nisin, methionine analogues, click chemistry, dimers, fluorescence
Lantibiotics are antimicrobial peptides harboring unusualpost-translationally modified amino acid residues such as
dehydroalanine (Dha) and dehydrobutyrine (Dhb), lanthio-
nine (Lan) and methyllanthionine (MeLan), that are
introduced by a promiscuous post-translational modification
(PTM) machinery.1,2 The unique biosynthetic pathways and
relatively low genetic complexity of biosynthesis make
lantibiotics good candidates for synthetic biology and
bioengineering, to expand the antimicrobial arsenal.2 Various
synthetic and biosynthetic strategies have been developed to
increase the diversity of lantibiotics.3−5 The uncommon amino
acids (Dha, Dhb, Lan, MeLan) in lantibiotics play an
important role in their biological activity and structural
stability. Other noncanonical amino acids (ncAAs) offer a
further highly diverse pool of building blocks that can
introduce unique physicochemical properties.6 By incorporat-
ing non-natural functional groups with unique features, we can
dramatically expand the chemical and functional space of
lantibiotic structures and enable the design of novel lantibiotics
with enhanced properties (e.g., stability, specificity, bioavail-
ability, and half-life).7−9 The use of this approach allows for
the in vivo production of new lantibiotics with an expanded
amino acid repertoire.8 Among ncAAs, the analogues of
methionine are of particular interest, as some of them (e.g.,
azidohomoalanine and homopropargylglycine) possess unique
reactive groups which can serve as chemical handles to
conjugate with fluorophores, glycans, PEGs, lipids, peptide
moieties, and other antimicrobial moieties through click
chemistry.10
Copper(I)-catalyzed azide−alkyne cycloaddition (CuAAC),
referred to as “click chemistry”, was first reported by Sharpless
and co-workers in 2001.11 It is a region-selective copper(I)
catalytic cycloaddition reaction between an azide and an alkyne
that gives rise to a triazole. Peptide modification using click
chemistry has been the subject of several studies for the
development of target-specific bacterial probes and for
expanding their bioactivity and application.12−17 Prompted
by these recent reports, we used nisin as a model to explore the
potential of this approach for lantibiotic engineering. Nisin is
the best studied lanthipeptide to date.18 It is produced by
Lactococcus lactis and has potent activity against a broad
spectrum of Gram-positive bacteria, including many antibiotic-
resistant organisms, such as methicillin-resistant Staphylococcus
aureus (MRSA) and vancomycin-resistant Enterococci (VRE).
Mature nisin, encoded by nisA as a linear precursor peptide (57
aa) that consists of a leader peptide (23 aa) and a propeptide
to be modified (34 aa), is released after modification and
cleavage of the leader.19 Gratifyingly, the modification
machinery of nisin has a broad substrate specificity, which
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allows for the divergence from the original core-peptide to
produce variant peptides.
Here, we describe the incorporation of six different
methionine analogues with unsaturated, unique chemical
handles and varying side chain length, i.e., Aha (azidohomoa-
lanine), Hpg (homopropargylglycine), Nle (norleucine), Eth
(ethionine), Nva (norvaline), and Alg (allyglycine), at four
different positions in the lantibiotic nisin by using a
methionine auxotrophic strain of Lactococcus lactis. Previous
studies have shown that with mutations at sites I4, M17, and
M21, nisin can retain or even have enhanced bioactivity.20 To
broaden the structural diversity and test the effects of single
replacements of methionine with respective analogues, four
single methionine nisin mutants, i.e., M17I, M21V, M17I-
M21V-M35, and I4M-M17I-M21V, were constructed. As
methionine is essential for the synthesis of post-translational
modification enzymes, a cross-expression system was devel-
oped utilizing separate promoters, allowing for the separate
induction of expression of target genes and biosynthetic
enzymes. The amino acid replacement and incorporation
efficiency of ncAAs into nisin derivatives were determined by
matrix assisted laser desorption/ionization time-of-flight
analyzer (MALDI-TOF) and liquid chromatography−mass
spectrometry (LC-MS). Twelve nisin derivatives were purified
in large scale by HPLC and their antimicrobial activities were
determined. In addition, six Aha- or Hpg-containing nisin
derivatives were coupled either mutually or with nisin ABC-
azide (A, B, and C denoting the first three lanthionine rings of
nisin; Figure 1), Cy5-azide and 6-FAM-alkyne through click
chemistry to obtain six dimeric nisin constructs, three nisin
hybrids, and six fluorescently labeled nisin variants.
■ RESULTS AND DISCUSSION
A Cross Expression System to Incorporate Methio-
nine Analogues into Nisin by Use of L. lactis as a Host.
Two in vivo approaches have been developed for incorporating
ncAAs into peptides.8 The first approach is “site-specific
incorporation”.21 For this method, the coexpression of
orthogonal amber suppressor aminoacyl-tRNA synthetase
(AARS/tRNA) pairs is necessary. Specific mutations can be
introduced into the peptide sequence by reassigning the amber
nonsense stop codon during translation. However, the
screening and development of orthogonal AARS/tRNA pairs
is time-consuming and the production yield of this method is
extremely low. Conversely, “residue-specific incorporation”,
the second approach, that generally does not suffer from such
drawback, is a more promising strategy.22 This method
typically involves replacing natural amino acids with the
ncAAs of interest by using auxotrophic strains. It is able to
generate broad and efficient structural diversity by directly
incorporating ncAAs via translation into bioactive peptides.
Various expression hosts have been developed for the
incorporation of ncAAs.7 Until now, the Gram-negative
Escherichia coli is the only prokaryotic expression host used
for the incorporation of methionine analogues.23−25 Here, the
Gram-positive expression host L. lactis, a methionine-
auxotrophic strain, is used for the incorporation of methionine
analogues into the lantibiotic nisin. After ribosomal synthesis
of the precursor peptide with 19 standard amino acids and with
variable methionine analogues, the unmodified prenisin is
processed by its dedicated modification machinery (Scheme
1). First, the serine and threonine residues in the core peptide
Figure 1. (A) A cross expression system with two plasmids. SczA, encoding the repressor of PczcD; PczcD, a zinc inducible promoter; nisA, encoding
NisA; repA and repC, encoding plasmid replication proteins; CmR, chloramphenicol resistance gene; PnisA, a nisin inducible promoter; nisB,
encoding NisB; nisT, encoding NisT; nisC, encoding NisC; EmR, erythromycin resistance gene. (B) Peptide sequence of nisin and nisin derivatives.
Lipid II binding site (rings AB), pore formation domain (rings CDE), and hinge region (NMK) are indicated; Positions 17, 21, and 35, which
served to incorporate methionine analogues of nisin are indicated; Dha, dehydroalanine; Dhb, dehydrobutyrine; A-S-A, lanthionine; Abu-S-A,
methyllanthionine; In blue, wildtype Met positions; In green, Met residues replaced by Ile or Val; In red, Met residues at novel positions. (C)
Structures of methionine and its analogues. Met, L-methionine; Aha, L-azidohomoalanine; Hpg, L-homopropargylglycine; Nle, L-norleucine; Eth, L-
ethionine; Nva, L-norvaline; Alg, L-allyglycine.
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are Dha and Dhb by the dehydratase NisB. The dehydrated
residues are then coupled to specific cysteine by the cyclase
NisC to form lanthionine rings. Subsequently, the modified
prenisin is transported out of the cell by the ABC-type
transporter NisT, and then the leader is cleaved off by the
extracellular protease NisP to liberate the active peptide.
As methionine is essential for the translation of post-
translational modification (PTM) enzymes and transporter, a
cross expression system, which allows for the expression of
prenisin derivatives and PTM enzymes and transporter at
different time was used for this study. L. lactis NZ9000 was
transformed with a plasmid encoding the expression of
NisBTC under the control of the PnisA promoter and the
other plasmid encoding the expression of prenisin derivatives
was controlled by the PczcD promoter. The expression of
NisBTC was first conducted by the supplementation of
Scheme 1. Incorporation of Methionine Analogues into Nisina
a(1) Cotranslational modifications, insertion of methionine analogues into the precursor peptide. (2) Post-translational modifications, converting
the linear precursor peptide into an active polycyclic peptide.
Figure 2. Coomassie-blue stained Tricine-SDS-PAGE gel. Each well contained TCA-precipitated prepeptides from 1 mL supernatant.
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methionine, after which the medium was replaced by new
medium lacking methionine, but containing methionine
analogues to express prenisin derivatives (Figure 1A).
Although the expression of the modification machinery
NisBTC was induced in advance, no effect on the modification
efficiency was observed.
Production of Nisin and Its Derivatives. There are two
methionine residues in the core peptide of nisin, which are
located at sites 17 and 21. Previous studies showed that nisin
with the mutation at sites I4, M17, and M21 could retain or
even have increased antimicrobial activity.20 To test the effects
of single methionine replacement with analogues in bioactive
nisin, four single methionine mutants, i.e., M17I, M21V, M17I-
M21V-M35, and I4M-M17I-M21V were constructed (Figure
1B). The choice for Ile or Val as substituents was to retain
good antimicrobial activity, since both residues share the
hydrophobic character of Met and are sterically not very
different, though branched. Six methionine analogues, i.e., Aha,
Hpg, Nle, Eth, Nva, and Alg were selected for the
incorporation (Figure 1C), and each combination was tested.
The expression level of nisin and its derivatives is shown in
Figure 2. The protein quantities in the first five lanes showed
that Aha, Hpg, Nle, and Eth can be incorporated into nisin and
its derivatives at varying levels. However, incorporation of Nva
and Alg was not observed at any moment, and addition of
these analogues to a culture lacking methionine led to arrested
cell growth. These results strongly indicate that Nva and Alg
cannot be incorporated by L. lactis. The highest production
yield was observed when normal methionine was supple-
mented. Effectively, a lower production yield was observed in
the presence of methionine analogues, in particular with Eth,
regardless of the position within the molecule. Methionine
analogue incorporation in nisin, M17I, and M21V gave much
higher yields of fully modified peptides than M17I-M21V-M35
and I4M-M17I-M21V, which may be due to the intolerance of
the modification machinery and/or the transporter to a change
of chemical structures at sites I4 and M35. Surprisingly, the
production yield of fully modified M21V is even higher than
that of WT nisin. To assess the presence of post-translational
modifications and incorporation of ncAAs, all samples were
further analyzed by HPLC and MALDI-TOF. The resulting
spectra showed that the production yield of nisin and its
derivatives with Aha and Hpg are much higher than the ones
with Nle and Eth. In addition, we found that Nle and Eth had a
negative influence on the dehydration rate, as large fractions of
7 times dehydrated peptides were observed.
LC-MS Analysis of Nisin Derivatives. In order to
estimate the incorporation efficiency of methionine analogues
at different positions, the precipitated precursor peptides were
subjected to LC-MS. The LC-MS data showed that the
incorporation efficiency of Aha and Hpg into mutants M17I,
M21V, and I4M-M17I-M21V was more than 91%, while the
incorporation efficiency of Nle and Eth was 88% and 71−73%,
respectively. Remarkably, the incorporation efficiency of Aha
and Hpg into M17I-M21V-M35 was at least 99.5%, and the
peaks of peptides containing methionine were undetectable.
However, the incorporation efficiency of Nle and Eth was only
51 and 71%, respectively. In the case of nisin, the incorporation
efficiency was 88% for Aha, 87% for Hpg, 77% for Nle, and
56% for Eth. Generally, the incorporation efficiency of ncAAs
declined in the order Aha > Hpg > Nle > Eth (Table 1).
Incorporation of Aha and Hpg into nisin, M17I, and M21V
did not affect the dehydration efficiency, as peptides with 7
times dehydrated residues were nearly undetectable, suggesting
they are excellent methionine surrogates. It may be due to the
rate of activation of Aha and Hpg by methionyl-tRNA
synthetase (MetRS) during translation, which finally results
in the higher yield and efficient modification. However,
introducing Nle and Eth resulted in a large fraction of peptides
with 7 times dehydration. It may be that the integration speed
of Nle and Eth during translation is relatively slow which leads
to a lower yield and insufficient modification. The dehydration
of M17I-M21V-M35 and I4M-M17I-M21V was dramatically
affected by the mutation. Additionally, methionine and
ethionine can be oxidized, and peaks corresponding to oxidized
products were indeed observed. Furthermore, the first
methionine of prenisin is usually cleaved by the enzyme
methionine aminopeptidase (MAP). However, a large portion
of precursor peptide produced by this system contained the N-
terminal Met. The molecular weight of both peaks is shown in
Table 2.
Antimicrobial Activity of Nisin and Its Derivatives. In
consideration of a sufficient production yield of the fully
modified peptides, 12 peptides containing methionine, Aha or
Hpg were purified in large scale for antimicrobial activity tests
(Figure 3). M. f lavus was used as a first indicator strain in an
agar-well diffusion assay to assess the antimicrobial activity.
The results showed that M17Aha-M21Aha, M17Hpg-
M21Hpg, M21V, M21V-M17Aha, and M21V-M17Hpg have
higher antimicrobial activity compared to WT nisin, and
mutant M21V showed the best activity with any of the three
amino acids. However, in all the cases, the activity of mutants
M17I and M17I-M21V-M35 decreased dramatically.
The MIC values were determined for L. lactis and six Gram-
positive pathogenic strains. The tested strains included two
Staphylococci, two Enterococci, Bacillus cereus and Listeria
monocytogenes (Table 3). The results showed that the
Table 1. Incorporation Efficiency of Nisin and Its
Derivatives Analyzed by LC-MSa





















a>99.5% means the peak of peptides containing methionine is
undetectable. The incorporation efficiency indicates the percentage of
the produced peptide with methionine analogues incorporated
completely.
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replacement of Met with Met analogues can alter the
antimicrobial activity and spectrum. Certain peptides retained
or even displayed higher activity against a specific strain, while
showing reduced activities against others, suggesting a possible
increase in selectivity. For example, M17Aha-M21Aha showed
improved activity against L. monocytogenes, but the activity
against the other strains was reduced when compared to nisin.
M21V has been reported to have enhanced bioactivity and
specific activity against all tested Gram-positive pathogens
including four VRE strains compared to WT nisin.26,27 In our
study, M21V showed reduced activities against two Enter-
ococci strains, but retained a high activity against others.
Improving the antimicrobial activity of nisin turned out to be
difficult. However, engineering nisin can generate new nisin
derivatives that have different properties and can be used for
specific targets. In addition, some nisin derivatives showed
different inhibition activity in solid media tests compared to
the broth MIC test. This phenomenon can be related to the
difference in diffusion ability.
Production of Dimeric Nisin Constructs and Nisin
Hybrids. The mode of action of nisin involves its binding to
lipid II, followed by membrane insertion, which leads to pore
formation. The pore-complex has a uniform and stable
structure, consisting out of eight nisin and four lipid II
molecules.28 In a previous study, a nisin dimer was prepared by
connecting two nisin molecules at the C-terminus through a
linker, which led to slightly increased pore-forming activity.13
As the nisin derivatives contain a clickable group (azide or
alkyne) at positions 17, 21, and 35, a setup was devised to
investigate how different orientations and multivalency
patterns of nisin dimers affect antimicrobial activity.29 M17I-
M21Aha, M17I-M21Hpg, M17I-M21V-M35Aha, M17I-
M21V-M35Hpg, M21V-M17Aha, and M21V-M17Hpg were
coupled either mutually or with nisin ABC-azide to generate
six dimeric nisin constructs and three nisin hybrids which were
characterized by MALDI-TOF (Supplementary Figure S1).
The antimicrobial activity of these dimers was tested against
M. f lavus by agar diffusion assays. The resulting growth
inhibition halos indicated the retainment of at least some
degree of activity in all variants. We found that the activity of
dimeric nisin constructs increased in order as reactions are
performed at the hinge region (position 21), the C-terminus
(position 35), and ring C (position 17). M17I-M21Aha +
M17I-M21Hpg is the least active dimeric nisin construct
(Figure 4A and 4B). Coupling at the hinge region may result in
increased steric hindrance and decreased flexibility and
therefore hindering its lipid II binding and pore formation




















































































































































































































































































































































































































































































Figure 3. Antimicrobial activity of nisin and its derivatives against
M. f lavus. In gray: values that are improved in comparison to nisin.
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is important for the activity, which is in accordance with
previous studies.30,31 Also M17I-M21V-M35Aha + M17I-
M21V-M35Hpg showed lower activity. Coupling at the C-
terminus of nisin gave rise to a dimeric nisin construct
containing two lipid II binding sites. However, the pore
formation ability may be weakened or abolished as the C-
terminus of nisin was involved in the connection since both C-
termini must flip simultaneously and insert in the membrane.
This involves the movement and reorientation of a bulky set of
amino acids, including the intertwined rings DE of each
monomer, through the membrane. M21V-M17Aha + M21V-
M17Hpg is the most active dimeric nisin construct. Coupling
at ring C gave the best activity, which may be due to the fact
that rings AB are still able to bind lipid II, while the hinge
region, rings DE and the linear C-terminus keeps their
individual flexibility, allowing the C-terminus of nisin to form
pores. Therefore, position 17 is the optimal site for coupling
moieties out of the 3 chosen positions. This study shows the
great potential of this strategy for linking active modules from
different peptides. Moreover, nisin ABC was obtained by
enzymatic digestion of nisin using chymotrypsin and it was
subsequently C-terminally functionalized with azidopropyl-
amine to generate nisin ABC-azide. Coupling M17I-M21Hpg,
M17I-M21V-M35Hpg, and M21V-M17Hpg with nisin ABC-
azide showed the same antimicrobial activity pattern as above;
i.e., activity is altered in ascending order as reactions are
Table 3. MIC Values (μM) of Nisin and Its Derivatives
peptide CAL-MRSA MW2-MRSA B. cereus E. faecalis E. faecium L. monocytogenes L. lactis
Nisin 10.39 5.19 5.19 2.60 0.32 2.60 0.020
M17Aha-M21Aha 19.99 13.33 6.66 3.33 0.42 1.67a 0.026
M17Hpg-M21Hpg 19.41 19.41 9.70 4.85 0.61 4.85 0.019a
M17I >19.92 >19.92 >19.92 19.92 2.49 4.98 0.622
M17I-M21Aha >17.42 >17.42 8.71 17.42 2.18 4.36 0.544
M17I-M21Hpg >19.08 >19.08 19.08 19.08 2.38 4.77 0.596
M21V 9.81a 2.45a 4.90a 4.90 0.61 2.45a 0.019a
M21V-M17Aha >19.72 19.72 19.72 9.86 0.62 4.93 0.039
M21V-M17Hpg >19.74 19.74 19.74 9.87 0.62 4.93 0.019a
M17I-M21V-M35 >18.33 >18.33 >18.33 >18.33 2.29 >18.33 0.573
M17I-M21V-M35Aha >19.96 >19.96 >19.96 >19.96 2.49 >19.96 0.624
M17I-M21V-M35Hpg >16.82 >16.82 >16.82 16.82 2.10 >16.82 >0.526
aMIC values that are retained or improved in comparison to nisin.
Figure 4. (A) Structure of three representative dimeric nisin constructs with reactions performed at the hinge region (position 21), the C-terminus
(position 35), and ring C (position 17). (B) Antimicrobial activity of six dimeric nisin and three nisin hybrids at equimolar concentrations against
M. f lavus with nisin as positive control. M17I-M21Aha + M17I-M21Hpg is the least active dimeric nisin construct whereas M21VM17Aha +
M21V-M17Hpg is the most active. Similarly, M17I-M21Hpg + Nisin ABC-azide is the least active nisin hybrid, whereas M21V-M17Hpg + Nisin
ABC-azide is the most active.
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performed to the hinge region, the C-terminus, and ring C,
respectively (Figure 4B).
Fluorescently Labeled Nisin Variants. Labeling of nisin
with fluorescent probes has greatly contributed to under-
standing its mechanism of action as shown in studies by
Scherer et al.32 and Descobry et al.33 The C-terminus of nisin is
the common site for labeling. However, introduction of a tag in
this position poses a considerable perturbation in the structure
and activity of nisin. Here, 6-FAM-alkyne and Cy5-azide
(Figure 5A) were successfully coupled at three different
positions (positions 17, 21, and 35) of nisin, and the resulting
compounds were characterized by MALDI-TOF (Supplemen-
tary Figure S2). The antimicrobial activity of six fluorescently
labeled nisin variants was retained (Figure 5B). Coupling 6-
FAM-alkyne and Cy5-azide at different positions of nisin
showed the same activity pattern as that obtained with dimeric
nisin constructs. Thus, M21V-M17Aha was found to be the
most suitable derivative for labeling with both 6-FAM-alkyne
and Cy5-azide. The localization of six fluorescently labeled
nisin variants interacting with E. faecium were studied by
fluorescence microscopy (Figure 5C). Fluorescence intensity
detection indicated that the labeled nisin conjugates were all
located at the cell membrane. Cy5-azide labeled nisin variants
showed lower activity than their 6-FAM-alkyne labeled
counterparts, and no aggregation was observed in cell division
sites. This may be due to the fact that Cy5-azide would affect
the binding of nisin conjugates to lipid II. M21V-M17Aha + 6-
FAM-alkyne (Figure 5D) was found to be the most potent
fluorescently labeled nisin variant, as it showed similar activity
to nisin. It was located at the septum of cell division sites
where the membrane-bound cell wall precursor lipid II
concentration is maximal. These results are in accordance
with previous studies using fluorescently labeled nisin A and
nisin Z, which indicated that both molecules were accumulat-
ing at the cell division sites of Bacillus subtilis and
L. monocytogenes, respectively.33,34 M21V-M17Aha + 6-FAM-
alkyne shows great potential as a tool to further study the
antibacterial mechanism of action of nisin and for under-
standing the mechanism of synergy of nisin with other
molecules on Gram-negative strain. Moreover, this strategy
can be extended to modify other ribosomally synthesized and
post-translationally modified peptides (RiPPs). While numer-
ous novel RiPPs have been reported, little is known about the
mechanism of action of these peptides. It would be highly
appropriate to use this method to modify such RiPPs with
biomarkers or fluorescence probes to investigate their
mechanism of action.
■ CONCLUSIONS
In summary, we have demonstrated for the first time the
incorporation of methionine analogues into RiPPs in L. lactis.
Four methionine analogues were successfully installed at four
distinct positions of the lantibiotic nisin. The genetic code of
L. lactis can be regarded to be expanded by incorporating
methionine analogues. The structural diversity was enhanced,
while retaining or even improving antimicrobial activity against
specific pathogens or Gram-positive bacteria. In addition, this
study underlines that the bio-orthogonal reactive groups of
ncAAs can serve as a platform for post-biosynthetic
modifications, such as conjugating with peptides, or functional
Figure 5. (A) Structure of fluorescent dyes 6-FAM-alkyne and Cy5-azide. (B) Antimicrobial activity of six fluorescently labeled nisin variants. (C)
Localization of six fluorescently labeled nisin variants by fluorescence microscopy. (D) Structure of the most potent fluorescently labeled nisin
variant M21V-M17Aha + 6-FAM-alkyne.
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labels (e.g., fluorescence). The insertion of ncAAs during
translation along with the possibility for their subsequent
modification (postsynthetic conjugation) could further expand
the chemical and functional space of RiPPs. Overall, our
experiments further exemplify one of the most important
applications of ncAA incorporation, that is, the functional,
structural, and chemical diversification of RiPPs. This study
provides an efficient method for RiPPs engineering by
incorporation of ncAAs and chemical coupling.
■ METHODS
Bacterial Strains, Plasmids, and Growth Conditions.
Strains and plasmids used in this study are listed in
Supplementary Table S1. All L. lactis strains were grown in
M17 broth supplemented with 0.5% (w/v) glucose at 30 °C
for genetic manipulation. Five μg/mL erythromycin and/or
chloramphenicol were added when it was necessary. Chemical
defined medium lacking tryptone (CDM-P)5 was specially
used for peptide expression and methionine analogues
incorporation.
Construction of Expression Vectors. The primers used
in this study are listed in Supplementary Table S2. The
molecular cloning techniques were performed following
standard protocols.35 The preparation of competent cells and
transformation were performed according to Holo and Nes.36
Fast digest restriction enzymes and ligase were used as
recommended by the manufacturer. Nisin derivatives with one
mutation in the core peptide (pCZ-nisA-M17I and pCZ-nisA-
M21V) were produced by spice overlap extension PCR. For
the construction of pCZ-nisA-M17I-M21V-M35 and pCZ-
nisA-I4M-M17I-M21V, nested PCR of pCZ-nisA was used to
introduce the mutation. The amplification was performed
using Phusion Polymerase (Thermo Scientific) following the
provider’s instructions and the primers are listed in
Supplementary Table S2. After amplification and digestion
with NheI and PaeI, it was ligated in pCZ-nisA digested with
the same enzymes. The ligation product was desalted and
transformed into L. lactis NZ9000. The plasmid was isolated
and sequenced to check the integrity of the sequence.
Methionine Analogues and Fluorescent Probes. The
methionine analogue L-homopropargylglycine (Hpg) was
purchased from Chiralix (Nijmegen, Netherlands). L-Azidoho-
moalanine (Aha), L-norleucine (Nle), L-norvaline (Nva), and
L-allyglycine (Alg) were purchased from Iris Biotech GmbH
(Marktredwitz, Germany). L-Ethionine (Eth) was purchased
from Alfa Aesar (Karlsruhe, Germany). 6-FAM-alkyne and
Cy5-azide were purchased from Jena Bioscience (Thuringia,
Germany).
Precursor Peptide Precipitation. L. lactis strains
harboring pIL3eryBTC and pCZ-nisA were grown overnight
in CDM-P with 5 μg/mL erythromycin and 5 μg/mL
chloramphenicol. Subsequently, the overnight culture was
diluted in 20 mL fresh CDM-P back to OD600 = 0.1. When the
OD600 reached 0.4−0.6, 10 ng/mL nisin was added to induce
the expression of NisBTC. Three hours later, the cells were
spun down at room temperature for 8 min at 5000 rpm and
then washed three times with CDM-P lacking methionine and
resuspended back in the initial volume of CDM-P lacking
methionine. The medium was supplemented with either
methionine (38 mg/L) or 50 mg/L methionine analogues,
and 0.5 mM ZnSO4 was added to induce peptide expression.
After overnight growth, the supernatant was harvested by
centrifugation at 8500 rpm for 20 min at 4 °C. The precursor
peptides were precipitated by Trichloroacetic acid (TCA) for
further analysis according to Link et al.37 Briefly, an ice-cold
100% TCA solution was added to the supernatant to reach a
final concentration of 10% TCA, and the solution was stored
overnight at 4 °C. The precipitated peptide was pelleted by
centrifugation at 8000 rpm for 60 min at 4 °C. The
supernatant was discarded and the pellet was washed with
ice-cold acetone in half the original culture volume by a second
centrifugation (8000 rpm, 45 min, 4 °C). The acetone was
discarded, and the remaining acetone was evaporated off over
several hours at room temperature. Dried pellets were
suspended in 300 μL 0.05% aqueous acetic acid solution.
Tricine-SDS-PAGE Analysis. The precipitated precursor
peptides were analyzed by Tricine-SDS-PAGE according to
Schagger et al.38 15 μL of each sample mixed with 4 μL loading
dye was loaded on the gel. Coomassie brilliant blue G-250 was
used to stain the gel.
LC-MS Analysis of Nisin Derivatives. The precipitated
precursor peptides were injected into the LC-MS system
consisting of an Ultimate 3000 UHPLC system coupled via a
HESI-II electrospray source with a Q-Exactive Orbitrap-based
mass spectrometer (all Thermo Scientific, San Jose, CA, USA).
Three μL of each sample was loaded onto a Kinetex EVO-C18
column (2.6 μm particles, 100 × 2.1 mm, Phenomenex). The
eluents for the LC separation were (A) water and (B)
Acetonitrile both containing 0.1% formic acid. The following
gradient was delivered at a flow rate of 0.5 mL/min: 10% B
until 1 min; then linear to 40% B in 9 min; linear to 80% B in 2
min; hold in 80% B for 2 min, after which a switch back to 10%
B was performed in 0.1 min. After 5 min of equilibration the
next injection was performed. The LC column was kept at 60
°C. The HESI-II electrospray source was operated with the
parameters recommended by the MS software for the LC flow
rate used (Spray voltage 3.5 kV (positive mode)); other
parameters were sheath gas 50 AU, auxiliary gas 10 AU, cone
gas 2 AU; capillary temperature 275 °C; heater temperature
400 °C. The samples were measured in positive mode from m/
z 500−2000 at a Resolution of 140 000 @ m/z 200. The
instrument was calibrated in positive mode using the Pierce
LTQ Velos ESI positive-ion calibration solution (Thermo
Fisher Scientific, Rockford, USA) (containing caffeine, the
tetrapeptide MRFA and a mixture of fluorinated phosphazines
ultramark 1621). The system was controlled using the software
packages Xcalibur 4.1, SII for Xcalibur 1.3 and Q-Exactive
Tune 2.9 (Thermo Fisher Scientific). The Xtract-algorithm
within Xcalibur was used for deconvolution of the isotopically
resolved data.
Purification of Nisin and Its Derivatives. To obtain
pure peptides for activity test, the supernatant of 1 L culture
was first incubated with purified NisP39 at 37 °C for 3 h to
cleave off the nisin leader, and then the supernatant was loaded
on a C18 open column (Spherical C18, particle size: 40−75
μm, Sigma-Aldrich). The column was washed and eluted with
different concentrations of buffer B (buffer A, Milli-Q with
0.1% TFA; buffer B, acetonitrile with 0.1% TFA). The active
fractions were lyophilized and further purified by HPLC using
an Agilent 1200 series HPLC with a RP-C12 column (Jupiter 4
μm Proteo 90A, 250 × 4.6 mm, Phenomenex). The peak that
is the fully modified peptide with the correct molecular weight
was lyophilized and stored as powder until further use.
MALDI-TOF Mass Spectrometry Characterization.
One μL of each sample was spotted, dried and washed with
Milli-Q water on the target. Subsequently, 1 μL of 5 mg/mL a-
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cyano-4-hydroxycinnamic acid (Sigma-Aldrich) was spotted on
top of the sample. An ABI Voyager DE Pro (Applied
Biosystems) matrix-assisted laser desorption/ionization time-
of-flight analyzer (MALDI-TOF) operating in linear mode
using external calibration was used to obtain mass spectra.40
Agar Well Diffusion Assay. Antimicrobial activity was
tested against M. f lavus according to protocols described
previously.40 HPLC purified and lyophilized peptides were
resuspended in 0.05% aqueous acetic acid solution and the
peptide amount was quantified by HPLC according to Schmitt
et al.5 0.15 nmol of sample was added to each well. The agar
plate was incubated at 30 °C overnight, after which the zone of
inhibition was measured.
Determination of the Minimal Inhibitory Concen-
tration (MIC). For the MIC assay, the indicator strains CAL-
MRSA, MW2-MRSA, E. faecalis, E. faecium, B. cereus,
L. monocytogenes, and L. lactis were first streaked on GM17
plate and cultured overnight. The peptide samples were diluted
with 0.05% acetic acid to a concentration of 4−128 μg/mL
(depending on the estimated activity of the peptide and the
strain tested). GM17 broth was used for the activity test
against E. faecium, L. monocytogenes, and L. lactis. MHB was
used for the activity test against CAL-MRSA, MW2-MRSA,
E. faecalis, and B. cereus. The MIC value test was performed
according to Wiegand et al.41
Preparation of Nisin ABC-Azide. Nisin was digested
using chymotrypsin to generate nisin ABC. The truncated nisin
molecule can be readily purified in accordance with protocols
reported previously.42 Nisin (180 mg) was dissolved in 150 mL
Tris buffer (25 mmol Tris acetate, pH 7.5) and the solution
was cooled on ice for 15 min. Then chymotrypsin (15 mg) was
added and stirred at room temperature for 15 min. The
reaction was performed at 30 °C for 16 h and an extra 15 mg
chymotrypsin was added. After 24 h incubation, another 15 mg
chymotrypsin was added and incubated for another 24 h. The
reaction mixture was acidified with HCl (1 M) to pH 4.0
followed by adding 3 mL MeCN and concentrated in vacuo.
The pure nisin ABC was purified from the mixture by RP-
HPLC and lyophilized to obtain a white powder (20 mg).
Nisin ABC (10 mg, 6.5 μmol) was dissolved in DMF (50 μL)
and azidopropylamine (44 μL, 43.2 mg, 432 μmol), PyBOP
(Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluoro-
phosphate) (9 mg, 17.2 μmol), and DIPEA (N,N-diisopropy-
lethylamine) (6 μL, 34.8 μmol) were added. The reaction was
vortexed for 20 min and subsequently quenched with 5 mL
buffer (H2O:MeCN, 95:5 + 0.1% TFA). The reaction mixture
was purified by HPLC and pure nisin ABC-azide was
lyophilized to obtain a white powder (8 mg).
Click Chemistry. A stock solution of CuSO4 (10 mg, 100
mM), BTTAA (2-(4-((bis((1-(tert-butyl)-1H-1,2,3-triazol-4-
yl)methyl)amino)methyl)-1H-1,2,3-triazol-1-yl)-acetic acid)
(25 mg, 50 mM), and sodium ascorbate (200 mg, 1 M) in
ddH2O were prepared, aliquoted and stored at −20 °C for
further use. M17I-M21Aha (70 μg, 0.02 μmol) and M17I-
M21Hpg (70 μg, 0.02 μmol) were dissolved in 100 mM
phosphate buffer (pH 7.0, final reaction volume: 200 μL).
Then, CuSO4 (4 μL, 0.4 μmol): BTTAA (40 μL, 2 μmol)-
premix were added followed by the addition of sodium
ascorbate (20 μL, 20 μmol). The reaction was performed at 37
°C for 1 h and purified directly by RP-HPLC. M17I-M21V-
M35Aha, M17I-M21V-M35Hpg, M21V-M17Aha, and M21V-
M17Hpg were reacted either mutually or with nisin ABC-azide
(40 μg, 0.02 μmol), Cy5-azide (5 μL, 10 mg/mL), or 6-FAM-
alkyne (4 μL, 10 mg/mL) at the above conditions. The
reaction was further scaled up in ratio to obtain more products.
The reaction products were purified directly by HPLC and the
peak with the correct molecular weight was lyophilized and
stored as powder until further use.
Fluorescence Microscopy. Cultures of overnight grown
E. faecium were diluted 1:100 and incubated in GM17 at 37 °C
for about 4 h to reach OD600 of 0.5. Then, 0.5 mL of culture
were centrifuged at 7000 rpm for 3 min. Fluorescently labeled
nisin variants were added into the Eppendorf tube with cells at
desired concentration in 100 μL saline solution and cells were
incubated at 37 °C for 30 min. After three other washes in
saline buffer, 0.6 μL bacterial suspensions and 1% low-melting-
point agar were added to a microscopy plate and the
localization of nisin variants were inspected with a Delta
Vision Elite inverted epifluorescence microscope (Applied
Precision, GE Healthcare, Issaquah, WA, USA) equipped with
a stage holder, a climate chamber, a seven-color combined set
InsightSSI Solid-state Illumination module and an sCMOS
camera (PCO AG, Kelheim, Germany). Excitation was set to
646 nm and emission to 662 nm to capture Cy5-azide
fluorescence. For 6-FAM-alkyne fluorescence, we employed
490 nm for excitation and emission at 513 nm. Images were
obtained by ImageJ software.
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